21+

Age Verification Required

You must be 21 years of age or older to enter this site. All products are for research use only and not intended for human consumption.

≥99% Purity GuaranteedThird-Party Lab TestedCOA With Every OrderSame-Day Shipping Before 3PMHeavy Metals & Sterility TestedHPLC Verified≥99% Purity GuaranteedThird-Party Lab TestedCOA With Every OrderSame-Day Shipping Before 3PMHeavy Metals & Sterility TestedHPLC Verified
Prime 9 Labs
HomeShopCOA LibraryFAQContact
Retatrutide 20mg

Retatrutide

LY3437943 · Triple GIP/GLP-1/Glucagon Agonist · Lyophilized Powder

$150
per vial · 20mg
≥99% Purity
3rd Party Tested
COA Available
Sterility Tested

Retatrutide is a next-generation triple receptor agonist targeting GIP (glucose-dependent insulinotropic polypeptide), GLP-1 (glucagon-like peptide-1), and glucagon receptors simultaneously. Studied in the context of metabolic syndrome, obesity-related pathways, and energy homeostasis research.

Size
Amount
1 Vial
Full price
Most Popular
2 Vials
Save 10%
Best Value
3 Vials
Save 15%

For Research Use Only · Not for Human Consumption

Product Overview

Retatrutide (LY3437943) is a novel unimolecular triple agonist developed for research into complex metabolic pathways. Unlike single or dual agonists, Retatrutide simultaneously engages three distinct receptor systems, making it an important compound for researchers studying overlapping metabolic signaling networks.

Prime 9 Labs supplies Retatrutide as a lyophilized powder at ≥99% purity confirmed by HPLC analysis. Each batch undergoes independent third-party testing at accredited U.S. laboratories. A batch-specific COA is included with every order.

Compound Details

  • Classification: Polypeptide / Triple receptor agonist
  • Targets: GIP receptor, GLP-1 receptor, Glucagon receptor
  • Approximate molecular weight: ~4,700 Da
  • CAS Number: 2381722-44-5
  • Form: Lyophilized white powder
  • Storage: −20°C, avoid light and moisture

Research Background

Retatrutide represents one of the most advanced peptide compounds under investigation for metabolic research. By engaging three independent receptor pathways, researchers can study how concurrent stimulation of GIP, GLP-1, and glucagon receptors influences energy balance and substrate metabolism.

Areas of Study

  • Multi-receptor metabolic signaling and pathway cross-talk
  • Energy expenditure and substrate utilization in cell models
  • Adipose tissue remodeling and lipid metabolism
  • Pancreatic beta-cell function and insulin secretion dynamics
  • Glucagon counter-regulatory mechanisms
  • Obesity pathway and appetite-regulatory network research

For research purposes only. Consult institutional protocols and peer-reviewed literature before use.

Certificate of Analysis

Retatrutide

GIP/GLP-1/Glucagon Triple Receptor Agonist

Certificate No. CP-QCC-2026-042130
Lot Number RT-APR26-P6W8D3
Release Date 2026.04.22
Product NameRetatrutide
CAS No.2381089-83-2
TypeSynthetic peptide
Country of OriginUnited States of America
Physical FormWhite lyophilized powder
Date of Analysis2026.04.21
Storage-20°C, light-protected, dry
Retest Date2028.04.19
UseLaboratory Research Use Only
Lot NumberRT-APR26-P6W8D3

Amino Acid Sequence

Y-Aib-Q-G-T-F-T-S-D-Y-S-I-αMeL-L-D-K(YE-AEEA-C20diacid)-A-Q-Aib-A-F-I-E-Y-L-L-E-G-G-P-S-S-G-A-P-P-S-N-NH2

39-mer GIP/GLP-1/glucagon triple agonist; C20 fatty diacid at K17 confirmed by LC-MS

Test ParameterSpecificationResult
AppearanceConforms to specification: White lyophilized powderPASS — White lyophilized powder
Purity / Assay≥99.0% (HPLC)PASS — 99.6%
IdentityConforms to reference standard (MS / HPLC)PASS — Confirmed
SolubilitySoluble in waterPASS — Clear solution
RELEASED FOR DISTRIBUTION  ·  Lot: RT-APR26-P6W8D3  ·  Release Date: 2026.04.22